From 2018 to 2022, the overall death rate for lung and bronchus cancer in the Kentucky was 61 per 100,000 for males and 43.2 per 100,000 for females. This statistic presents the death rates for lung and bronchus cancer in the United States from 2018 to 2022, by state and gender.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Lung Cancer Deaths reports the number, crude rate, and age-adjusted mortality rate (AAMR) of deaths due to lung cancer.
https://digital.nhs.uk/about-nhs-digital/terms-and-conditionshttps://digital.nhs.uk/about-nhs-digital/terms-and-conditions
Legacy unique identifier: P00508
As of 2022, the age-standardized mortality rate of lung cancer worldwide was 16.8 per 100,000 population. At this time, the mortality rate of lung cancer was highest in Polynesia. This statistic shows the age-standardized mortality rate of lung cancer worldwide as of 2022, by region.
https://digital.nhs.uk/about-nhs-digital/terms-and-conditionshttps://digital.nhs.uk/about-nhs-digital/terms-and-conditions
Mortality from lung cancer (ICD-10 C33-C34 equivalent to ICD-9 162). To reduce deaths from lung cancer. Legacy unique identifier: P00509
Rate: Number of deaths due to cancer of the trachea, bronchus, and lung per 100,000 Population.
Definition: Number of deaths per 100,000 with malignant neoplasm (cancer) cancer of the trachea, bronchus, and lung as the underlying cause (ICD-10 codes: C33-C34).
Data Sources:
(1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html
(2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health
(3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development
Death rate has been age-adjusted by the 2000 U.S. standard population. Single-year data are only available for Los Angeles County overall, Service Planning Areas, Supervisorial Districts, City of Los Angeles overall, and City of Los Angeles Council Districts.Lung cancer is a leading cause of cancer-related death in the US. People who smoke have the greatest risk of lung cancer, though lung cancer can also occur in people who have never smoked. Most cases are due to long-term tobacco smoking or exposure to secondhand tobacco smoke. Cities and communities can take an active role in curbing tobacco use and reducing lung cancer by adopting policies to regulate tobacco retail; reducing exposure to secondhand smoke in outdoor public spaces, such as parks, restaurants, or in multi-unit housing; and improving access to tobacco cessation programs and other preventive services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.
In 2022, the mortality rate of lung cancer in the European was **** per 100,000 men and **** per 100,000 women. Among men the mortality rate was highest in Hungary and lowest in Sweden being *** and **** per 100,000 respectively. Hungary was also the country with the highest lung cancer mortality rate in women with **** per 100,000 women. The lowest was in Lithuania with **** per 100,000 women. In most EU countries, there was a marked difference between the mortality of lung cancer in men and women.
Open Government Licence 3.0http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/
License information was derived automatically
Deaths from lung cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data
Cancer Rates for Lake County Illinois. Explanation of field attributes: Colorectal Cancer - Cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine). This is a rate per 100,000. Lung Cancer – Cancer that forms in tissues of the lung, usually in the cells lining air passages. This is a rate per 100,000. Breast Cancer – Cancer that forms in tissues of the breast. This is a rate per 100,000. Prostate Cancer – Cancer that forms in tissues of the prostate. This is a rate per 100,000. Urinary System Cancer – Cancer that forms in the organs of the body that produce and discharge urine. These include the kidneys, ureters, bladder, and urethra. This is a rate per 100,000. All Cancer – All cancers including, but not limited to: colorectal cancer, lung cancer, breast cancer, prostate cancer, and cancer of the urinary system. This is a rate per 100,000.
This map service portrays the number of deaths per 100,000 people per square mile from lung and colon cancer. It displays the distribution of lung and colon cancer across the United States. Pop-ups show attributes such as state name, county name, number of colon or lung cancer deaths, and square miles per area.Lung Cancer: Death due to malignant neoplasm of the trachea, bronchus and lung.Colon Cancer: Death due to malignant neoplasm of the colon, rectum and anus.This data was sourced from: Community Health Status Indicators_Other Health Datapalooza focused content that may interest you: Health Datapalooza Health Datapalooza
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Abstract Objective: To identify the socioepidemiologic and histopathologic patterns of lung cancer patients in the Middle Euphrates region. Patients and Methods: This study analyzed medical information from lung cancer patients at the Middle Euphrates Cancer Center in Iraq from January 2018 to December 2023. Demographic information (age, gender, residency, and education level) as well as clinical details (histopathological categorization) were obtained. The inclusion criteria included all confirmed lung cancer cases, while cases with inadequate data or non-lung cancer diagnosis were omitted. The data were analyzed using IBM SPSS Statistics (version 26). The data summarized using descriptive statistics, and chi-square tests used to identify correlations between categorical variables at a significance level of p < 0.05. Ethical approval was obtained from the relevant institutional review board. Results: A total of 1162 patients were included with mean age at diagnosis(64.47±11.45) years. Majority of patients are over 60 years (64.4%), followed by (40–60 years), 34%, and the least affected group is under 40 years (1.6%). Males account for the majority of cases (68%), while females about 32%, with male:female ratio that fluctuate around 2:1. Illiterate patients and those with low education levels represent the largest proportion accounting for about 87.9% of the study population. Squamous Cell Carcinoma (SCC) is the most frequent subtype (41.7%), followed closely by Adenocarcinoma (AC) at 37%, and Small Cell Lung Cancer (SCLC), 10.5%. Although SCC is the predominant subtype overall, AC incidence is increasing overtime (from 31.7% in 2018 to 41.4% in 2023) with predominance in females, younger and higher educated groups. While the percentage of SCLC and other less common subgroups remained relatively stable over time, there is a significant reduction in NSCLC-NOS diagnoses (from 11.1% in 2018 to 3.2% in 2023). Conclusions: In Iraq, specifically in the Middle Euphrates region, lung cancer is a major public health issue in the elder age groups. The two main subtypes, SCC and AC, are the main contributors, with obvious increment in AC cases in the recent years. The shifting trends indicate the urgent need for improved screening strategies, focused preventative initiatives, and customized treatment plans in view of changing risk profiles.
In 2020, approximately ** men and ** women per 100,000 population died from lung cancer in England and Wales. During the provided time interval, there has been a noticeable decrease in the mortality of lung cancer among men, while the rate among women has remained at similar levels since the year 2000.
Attribution-NonCommercial 3.0 (CC BY-NC 3.0)https://creativecommons.org/licenses/by-nc/3.0/
License information was derived automatically
Lung Cancer Mortality Data
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
ObjectiveLung cancer is responsible for millions of deaths yearly, and its burden is severe worldwide. This study aimed to investigate the burden of lung cancer in the population of Wuhan based on the surveillance data from 2010 to 2019.MethodsData of this study was obtained from the Mortality Register System established by the Wuhan Center for Disease Control and Prevention. The study systematically analyzed the burden of lung cancer deaths in the population of Wuhan and its 13 administrative regions from 2010 to 2019 via the Joinpoint regression models, Age-Period-Cohort (APC) models, and decomposition analysis.ResultsThis study found the upward and downward trends in the age-standardized mortality rates (ASMRs) and age-standardized years of life lost rates (ASYLLRs) of lung cancer from 2010 to 2019. In Joinpoint regression models, the corresponding estimated annual percentage change (EAPC) were 1.00% and -1.90%, 0.60%, and -3.00%, respectively. In APC models, lung cancer mortality tended to increase with age for both sexes in Wuhan, peaking at the 85-89 age group; The period effects for different populations have started to gradually decline in recent years. In addition, the cohort effects indicated that the risk of lung cancer death was highest among those born in the 1950s-1955s, at 1.08 (males) and 1.01 (females). Among all administrative districts in Wuhan, the ASMR of lung cancer in the Xinzhou District has remained the highest over the study period. In decomposition analysis, both population aging (P
MIT Licensehttps://opensource.org/licenses/MIT
License information was derived automatically
This dataset contains Cancer Incidence data for Lung Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are segmented by sex (Both Sexes, Male, and Female) and age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.
It is estimated that in 2024 there will be a total of 124,730 deaths due to lung and bronchus cancer in the United States. Florida is estimated to account for the highest number of these deaths. This statistic presents the estimated number of lung and bronchus cancer deaths in the United States in 2025, by state.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
BackgroundUnderstanding the effects of demographic drivers on lung cancer mortality trends is critical for lung cancer control. We have examined the drivers of lung cancer mortality at the global, regional, and national levels.MethodsData on lung cancer death and mortality were extracted from the Global Burden of Disease (GBD) 2019. Estimated annual percentage change (EAPC) in the age-standardized mortality rate (ASMR) for lung cancer and all-cause mortality were calculated to measure temporal trends in lung cancer from 1990 to 2019. Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.ResultsDespite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. This increase was due to the changes in the number of deaths attributable to population aging (59.6%), population growth (56.7%), and non-GBD risks (3.49%) compared with 1990 data. Conversely, the number of lung cancer deaths due to GBD risks decreased by 19.8%, mainly due to tobacco (−12.66%), occupational risks (−3.52%), and air pollution (−3.47%). More lung cancer deaths (1.83%) were observed in most regions, which were due to high fasting plasma glucose levels. The temporal trend of lung cancer ASMR and the patterns of demographic drivers varied by region and gender. Significant associations were observed between the contributions of population growth, GBD risks and non-GBD risks (negative), population aging (positive), and ASMR in 1990, the sociodemographic index (SDI), and the human development index (HDI) in 2019.ConclusionPopulation aging and population growth increased global lung cancer deaths from 1990 to 2019, despite a decrease in age-specific lung cancer death rates due to GBD risks in most regions. A tailored strategy is needed to reduce the increasing burden of lung cancer due to outpacing demographic drivers of epidemiological change globally and in most regions, taking into account region- or gender-specific risk patterns.
https://creativecommons.org/publicdomain/zero/1.0/https://creativecommons.org/publicdomain/zero/1.0/
This is a subset of data available from the US National Lung Screening Trial (NLST). The data contains information about current and former smokers who were observed for 7 years and were tested for lung cancer each year. No non-smokers were involved in the trial.
Data contains: - pid - anonymous identifier of a person - age - age of a person at the start of the trial - gender - Male/Female - race - the race of a person - smoker - Former/Current (Former is defined as quit smoking in last 15 years) - days_to_cancer - number of days passed since the trial when the cancer was first observed - stage_of_cancer - the stage of cancer when the cancer was first observed
Full trial metadata is available at https://wiki.cancerimagingarchive.net/download/attachments/5800702/package-nlst-780.2021-05-28.zip?version=1&modificationDate=1633562878492&api=v2
In 2019, approximately ** men and ** women per 100,000 population died from lung cancer in England. The North East of England had the highest mortality from lung cancer for both genders with a rate of approximately ** men and ** women per 100,000 population.
From 2018 to 2022, the overall death rate for lung and bronchus cancer in the Kentucky was 61 per 100,000 for males and 43.2 per 100,000 for females. This statistic presents the death rates for lung and bronchus cancer in the United States from 2018 to 2022, by state and gender.